Page 21 - PHESGO (PERTUZUMAB-TRASTUZUMAB) - Product Monograph

REFERENCES
1. GLOBOCAN (2018a). Breast Fact Sheet. Available from:
http://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. (Accessed January 2020).
2. Wolff AC, Hammond ME, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2
testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical
practice guideline update. J Clin Oncol. 2013;31(31):3997-4013. doi:10.1200/JCO.2013.50.9984
3. Pathmanathan N, Geng JS, Li W, et al. Human epidermal growth factor receptor 2 status of gastric cancer
patients in Asia: results from a large, multicountry study. Asia Pac J Clin Oncol. 2017;13(3):249-260.
doi:10.1111/ajco.12653
4. DeSantis, C. E., Bray, F., Ferlay, J., Lortet-Tieulent, J., Anderson, B. O. & Jemal, A. International variation in female
breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2015; 24(10), 1495–506.
5. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D. & Bray, F.
Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J
Cancer. 2015; 136(5), E359–86.
6. Howlader, N., Noone, A. M., Krapcho, M., Miller, D., Bishop, K., Kosary, C. L., Yu, M., Ruhl, J., Z., T., Mariotto, A., et al.
SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD,
https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER
web site, April 2017.
7. Lidgren, M., Wilking, N., Jonsson, B. &Rehnberg, C. Health related quality of life in different states of breast
cancer. Qual Life Res. 2007b; 16(6), 1073–81.
8. Gokgoz, S., Sadikoglu, G., Paksoy, E., Guneytepe, U., Ozcakir, A., Bayram, N. &Bilgel, N. Health related quality of
life among breast cancer patients: a study from Turkey. Global Journal of Health Science. 2011; 3(2), 140–152.
9. Radice, D. &Redaelli, A. Breast cancer management: quality-of-life and cost considerations.
Pharmacoeconomics. 2003; 21(6), 383–96.
10. Grabsch, B., Clarke, D. M., Love, A., McKenzie, D. P., Snyder, R. D., Bloch, S., Smith, G. & Kissane, D. W.
Psychological morbidity and quality of life in women with advanced breast cancer: a cross-sectional survey.
Palliat Support Care. 2006; 4(1), 47–56.
11. Mehnert, A. & Koch, U. Prevalence of acute and post-traumatic stress disorder and comorbid mental
disorders in breast cancer patients during primary cancer care: a prospective study. Psychooncology. 2007;
16(3), 181–8.
12. Paskett, E. D., Naughton, M. J., McCoy, T. P., Case, L. D. & Abbott, J. M. The epidemiology of arm and hand
swelling in premenopausal breast cancer survivors. Cancer Epidemiol Biomarkers Prev, 2007; 16(4), 775–82.
13. Kim, P. Cost of cancer care: the patient perspective. J Clin Oncol; 2007; 25(2), 228–32.
14. Azim et al., 2011 Azim, H. A., Jr., de Azambuja, E., Colozza, M., Bines, J. &Piccart, M. J. Long-term toxic effects of
adjuvant chemotherapy in breast cancer. Ann Oncol. 2011; 22(9), 1939–47.
15. Neven, P., Van Calster, B., Van den Bempt, I., Van Huffel, S., Van Belle, V., Hendrickx, W., Decock, J., Wildiers, H.,
Paridaens, R., Amant, F., et al. Age interacts with the expression of steroid and HER-2 receptors in operable
invasive breast cancer. Breast Cancer Res Treat. 2008; 110(1), 153–9.
16. Kwan, M. L., Kushi, L. H., Weltzien, E., Maring, B., Kutner, S. E., Fulton, R. S., Lee, M. M., Ambrosone, C. B. &Caan, B.
J. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast
Cancer Res. 2009; 11(3), R31.

M-AE-00000086 21